Indoco Remedies receives EIR from USFDA

Alembic Pharmaceuticals on Tuesday said it has received final approval from the US health regulator for its generic Silodosin capsules used in treatment of benign prostatic hyperplasia. The approval by the US Food and Drug Administration (USFDA) for Silodosin capsules is for multiple strengths of 4 mg and 8 mg, the company said in a regulatory filing. It is therapeutically equivalent to the reference listed drug product Rapaflo Capsules, 4 mg and 8 mg, of Allergan Sales, LLC, it added. Silodosin capsule is indicated for treatment of the signs and symptoms of benign prostatic hyperplasia. Citing IQVIA data, the company said Silodosin capsules have an estimated market size of USD 114 million for 12-months ending June 2019. Alembic now has a total of 108 ANDA approvals (96 final approvals and 12 tentative approvals) from USFDA, the company said.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!